Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1015-1022

  Chan, J Y H ^a   Chin, W ^a   Liew, C T ^a   Chang, K S ^b   Johnson, P J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene expression regulation; Hepatitis B; Hepatocellular carcinoma; Neoplastic; PML; Suppressor genes

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION; HEPATITIS, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032101805     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10138-1     Document Type: Article

References (29)

1. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
2. Knudson A. G. Anti-oncogenes and human cancer. Proc Natl Acad Sci USA. 90:1993;10914-10921.
3. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
4. Smith M. L., Fornace A. J. Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol. 7:1995;69-75.
5. Diverio D., Riccioni R., Mandelli F., LoCoco F. The PML/RAR-alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica. 80:1995;155-160.
6. Chen S. J., Wang Z. Y., Chen Z. Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells. 13:1995;22-31.
7. Lavau C., Dejean A. The t(15;17) translocation in acute promyelocytic leukemia. Leukemia. 8:(Suppl 2):1994;S9-S15.
8. Chang KS, Stass SA, Chu DT, et al. Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation break-point in acute promyelocytic leukemia. Mol Cell Biol 1992, 12, 800-810.
9. Mu Z. M., Chin K. V., Liu J. H., Lozano G., Chang K. S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 14:1994;6858-6867.
10. Liu J. H., Mu Z. M., Chang K. S. PML suppresses oncogenic transformation of NIH-3T3 cells by activated neu. J Exp Med. 181:1995;1965-1973.
11. Chang K. S., Fan Y. H., Andreeff M., Liu J., Mu Z. M. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood. 85:1995;3646-3653.
12. Le X. F., Yang P., Chang K. S. Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene PML. J Biol Chem. 271:1996;130-135.
13. Doucas V, Ishov AM, Romo A, et al. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Gene Dev 1996, 10, 196-207.
14. Puvion-Dutilleul F., Chelbi-Alix M. K., Koken M., Quignon F., Puvion E., The H. de. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp Cell Res. 218:1995;9-16.
15. Szekely L., Pokrovskaja K., Jiang W. Q., The H. de, Ringertz N., Klein G. The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol. 20:1996;2562-2568.
16. Everett R. D., Maul G. G. HSV-1 IE protein Vmwl 10 causes redistribution of PML. EMBO J. 13:1994;5062-5069.
17. Lavau C, Marchio A, Fagioli M, et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995, 11, 871-876.
18. Koken MHM, Linares-Cruz G, Quignon F, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995, 10, 1315-1324.
19. Terris B, Baldin V, Dubios S, et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 1995, 55, 1590-1597.
20. Gambacorta M, Flenghi L, Fagioli M, et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 1996, 149, 2023-2035.
21. Johnson P. J. The epidemiology of hepatocellular carcinoma. Eur J Gastroentero Hepato. 8:1996;845-849.
22. Ho S., Cheng P., Johnson P. J. Isoelectric focusing of alpha-fetoprotein in patients with hepatocellular carcinomas; frequency of specific banding patterns at non-diagnostic levels. Br J Cancer. 73:1996;985-989.
23. Teeter LD, Estes M, Chan JYH, et al. Activation of distinct multidrug resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinogen 1993, 8, 67-73.
24. Grotzinger T., Jensen K., Will H. The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J Biol Chem. 271:1996;25253-25260.
25. Boddy M. N., Howe K., Eikin L. D., Solomon E., Freemont P. S. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia. Oncogene. 13:1996;971-982.
26. Desbois C., Rousset R., Banntignies F., Jalinot P. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-1 Tax oncoprotein. Science. 273:1996;951-953.
27. Lam Y. W., Ammerlaan W., O W. S., Kroese F., Opstelten D. Cell type and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55. Exp Cell Res. 221:1995;344-356.
28. Maul G. G., Yu E., Ishov A. M., Epstein A. L. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J Cell Biochem. 59:1995;498-513.
29. Chan J. Y. H, Li L., Fan Y.-H., Mu Z.-M., Zhang W.-W., Chang K.-S. Cell-cycle regulation of DNA damage-induced expression of the suppressor gene PML. Biochem Biophys Res Commun. 240:1997;640-646.